Search details
1.
NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.2021.
J Natl Compr Canc Netw
; 19(3): 254-266, 2021 03 02.
Article
in English
| MEDLINE | ID: mdl-33668021
2.
Long term follow-up of neoadjuvant chemotherapy for non-small cell lung cancer (NSCLC) investigating early positron emission tomography (PET) scan as a predictor of outcome.
BMC Cancer
; 19(1): 70, 2019 Jan 14.
Article
in English
| MEDLINE | ID: mdl-30642285
3.
NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 1.2020.
J Natl Compr Canc Netw
; 17(12): 1464-1472, 2019 12.
Article
in English
| MEDLINE | ID: mdl-31805526
4.
Racial disparity in oncologic and quality-of-life outcomes in patients with locally advanced head and neck squamous cell carcinomas enrolled in a randomized phase 2 trial.
Cancer
; 124(13): 2841-2849, 2018 07 01.
Article
in English
| MEDLINE | ID: mdl-29669181
5.
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.
Lancet Oncol
; 17(11): 1497-1508, 2016 Nov.
Article
in English
| MEDLINE | ID: mdl-27745820
6.
A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment.
Cancer
; 121(16): 2749-56, 2015 Aug 15.
Article
in English
| MEDLINE | ID: mdl-25913680
7.
Neutrophil to lymphocyte ratio and peripheral blood biomarkers correlate with survival outcomes but not response among head and neck and salivary cancer treated with pembrolizumab and vorinostat.
Head Neck
; 45(2): 391-397, 2023 02.
Article
in English
| MEDLINE | ID: mdl-36412064
8.
Peripheral lymphocytes and lactate dehydrogenase correlate with response and survival in head and neck cancers treated with immune checkpoint inhibitors.
Cancer Med
; 12(8): 9384-9391, 2023 04.
Article
in English
| MEDLINE | ID: mdl-36806947
9.
A Phase II study of pulse dose imatinib mesylate and weekly paclitaxel in patients aged 70 and over with advanced non-small cell lung cancer.
BMC Cancer
; 12: 449, 2012 Oct 03.
Article
in English
| MEDLINE | ID: mdl-23033932
10.
The management of patients with stage IIIA non-small cell lung cancer with N2 mediastinal node involvement.
J Natl Compr Canc Netw
; 10(5): 599-613, 2012 May.
Article
in English
| MEDLINE | ID: mdl-22570291
11.
Impact of Diagnostic Delays on Lung Cancer Survival Outcomes: A Population Study of the US SEER-Medicare Database.
JCO Oncol Pract
; 18(6): e877-e885, 2022 06.
Article
in English
| MEDLINE | ID: mdl-35119911
12.
Performance status (PS) as a predictor of poor response to immune checkpoint inhibitors (ICI) in recurrent/metastatic head and neck cancer (RMHNSCC) patients.
Cancer Med
; 11(22): 4104-4111, 2022 11.
Article
in English
| MEDLINE | ID: mdl-35349227
13.
Prognostic Value of Early Fluorodeoxyglucose-Positron Emission Tomography Response Imaging and Peripheral Immunologic Biomarkers: Substudy of a Phase II Trial of Risk-Adaptive Chemoradiation for Unresectable Non-Small Cell Lung Cancer.
Adv Radiat Oncol
; 7(2): 100857, 2022.
Article
in English
| MEDLINE | ID: mdl-35387421
14.
High End-of-Life Health Care Utilization in a Contemporary Cohort of Head and Neck Cancer Patients Treated with Immune Checkpoint Inhibitors.
J Palliat Med
; 25(4): 614-619, 2022 04.
Article
in English
| MEDLINE | ID: mdl-34847733
15.
Value-Based Care in Lung Cancer.
Oncologist
; 21(8): 903-6, 2016 08.
Article
in English
| MEDLINE | ID: mdl-27256872
16.
Motesanib diphosphate in progressive differentiated thyroid cancer.
N Engl J Med
; 359(1): 31-42, 2008 Jul 03.
Article
in English
| MEDLINE | ID: mdl-18596272
17.
Impact of Clinical Trial Participation on Survival of Patients with Metastatic Non-Small Cell Lung Cancer.
Clin Lung Cancer
; 22(6): 523-530, 2021 11.
Article
in English
| MEDLINE | ID: mdl-34059474
18.
Adaptive Fluorodeoxyglucose-Positron Emission Tomography Based Chemotherapy Selection for Metastatic Non-small Cell Lung Cancer.
Cureus
; 13(10): e18804, 2021 Oct.
Article
in English
| MEDLINE | ID: mdl-34796077
19.
Effect of Clinical Trial Participation on Costs to Payers in Metastatic Non-Small-Cell Lung Cancer.
JCO Oncol Pract
; 17(8): e1225-e1234, 2021 08.
Article
in English
| MEDLINE | ID: mdl-34375561
20.
Long-Term Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLC.
J Thorac Oncol
; 16(1): 162-168, 2021 01.
Article
in English
| MEDLINE | ID: mdl-33069888